|Public Health Preparedness and Response

The American public continually confronts medical events such as emerging infectious diseases, terrorist threats, or natural disasters. Several federal agencies participate collaboratively and unilaterally within their mission space in building contingency plans and executing programs that address these potential events; from prevention of the events to active response engagement. Tunnell Government Services (TGS) supports several of these agencies through our biomedical scientific understanding of the threats, our expertise in preventative and therapeutic product life cycle development, and our experience in consequence management procedures. As noted below, our capabilities range from early identification of threats to final manufacturing and distribution cold chain management to ultimate storage at user’s locations.

♦ Epidemiological studies to identify threat severity and characteristics as well as response program effecti veness

♦ Laboratory characterization of threats

♦ Marketplace assessments of available countermeasure technologies – both FDA approved or in development

♦ Intelligence services to monitor political and scientific environment to identify and target threats

♦ Requirements generation / definition

♦ Medical product development life cycle support

♦ Medical product logistics management

♦ Program evaluation and improvement

♦ Critical manufacturing infrastructure support

♦ Interagency support and participation

♦ Health policy and clinical practice development

Reference Materials

WhitePaper: Achieving more Efficient and Effective Clinical Trials
Biologics/Biotechnology
Project Brief–Program Support–NIH
Integrated Sustainable Solutions

Press

Jens H. Kuhn, Ph.D., co-authors article on Phylogenetic Analysis of Avian Infectious Bronchitis Virus Isolates from Morocco: a Retrospective Study. Published in Virologica Sinica
Jens H. Kuhn, Ph.D., co-authors article on Phylogenetic Analysis of Avian Infectious Bronchitis Virus Isolates from Morocco:  a Retrospective Study.  Published in Virologica Sinica

4/12/17

 

View Abstract»

Jens H. Kuhn, Ph.D., Contributes to Research Paper on Crimean-Congo Hemorrhagic Fever
Jens H. Kuhn, Ph.D., Contributes to Research Paper on Crimean-Congo Hemorrhagic Fever

06/01/2011

A research paper about Crimean-Congo hemorrhagic fever is now available via ScienceDirect. Jens H. Kuhn, of Tunnell Government Services, is a contributing author.  Purchase the article to find out more about the development of prophylaxis and therapy for CCHF and discuss future prospects for vaccine and drug development.

View Abstract»

Yingyun Cai, Ph.D., Provides Insight on an Immunotoxin Targeting the gH Glycoprotein of KSHV
Yingyun Cai, Ph.D., Provides Insight on an Immunotoxin Targeting the gH Glycoprotein of KSHV

06/30/2011

Tunnell Government Services, Inc. contributor Yingyun Cai shared in-depth research in a recent study on an immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection.  These findings suggest that selective killing of virus-producing cells might represent a novel therapeutic strategy.  To find out more, read the entire abstract and purchase the study via ScienceDirect.

View Abstract»

Julie Dyall, Ph.D. and Catherine Jett, MPH Participate in Comparative Analysis of the Monkeypox Virus Infection
Julie Dyall, Ph.D. and Catherine Jett, MPH Participate in Comparative Analysis of the Monkeypox Virus Infection

02/06/2012

Tunnell Government Services consultants Julie Dyall, Ph.D. and Catherine Jett, MPH,  were two of the co-authors of a recent article that investigated the geographic expansion of the Monkeypox virus and its fatal potential.  They studied various forms of inoculations with the goal of determining the best form of treatment for nonhuman primates. Please click below to see the results of their investigation.

View Abstract»

Victoria Wahl-Jenson, Ph.D. Participates in Research of Variola Virus
Victoria Wahl-Jenson, Ph.D. Participates in Research of Variola Virus

02/06/2012

Tunnell Consultant, Victoria Wahl-Jenson, Ph.D.  co-authored an article in Plos One about research into the variola virus, the need for development of antivirals and improved vaccines and the possibility of the virus being used in bioterrorism.

View Abstract»

Jens H. Kuhn, a virologist at the National Institutes of Health and a Tunnell Government Services employee, cited the detection of possible Ebola antibodies in what is now the Democratic Republic of Congo in the 1980s.
Jens H. Kuhn, a virologist at the National Institutes of Health and a Tunnell Government Services employee, cited the detection of possible Ebola antibodies in what is now the Democratic Republic of Congo in the 1980s.

04/21/2015

View Abstract»

Jens Kuhn, Ph.D., Co-Authors Chapter on Biological Threats
Jens Kuhn, Ph.D., Co-Authors Chapter on Biological Threats

07/28/2016

Tunnell Principal Jens Kuhn, Ph.D., recently co-authored an article on “The Soviet Biological Warfare Program” for a publication titled Biological Threats in the 21st Century: The Politics, People, Science and Historical Roots”.  To read more about the book or to purchase a copy please go to

View Abstract»

Jens Kuhn Co-Authors Article on Ebola Virus
Jens Kuhn Co-Authors Article on Ebola Virus

08/16/2016

In 2013, Ebola virus was identified as the etiological agent of a large disease outbreak in Western Africa including almost 30,000 infections and more than 11,000 deaths, including case exportations to Europe and North America. These large case numbers resulted in medical countermeasure development against Ebola virus disease becoming a global public-health priority. This review summarizes the status quo of candidate vaccines against Ebola virus disease, with a focus on those that are currently under evaluation in clinical trials. Click here to read more about the article.

View Abstract»

Jens Kuhn, Ph.D., Co-Authors Article on Biological Weapons
Jens Kuhn, Ph.D., Co-Authors Article on Biological Weapons

09/14/2016

Tunnell Consultant, Jens Kuhn, Ph.D., has co-authored a chapter on “Biologische Waffen – eine Herausfordering an Diagnostik, Therapie, Klinik und Pravention (Biological Weapons – a challenge for diagnostics, therapy, clinics and prevention)” Medizinische Mikrobiologie und Infektiologie (Medical Microbiology and Infectiology), 8th ed. Spring-Verlag, Berlin, Germany,  ISBN: 978-3-662-48678-8.

View Abstract»

The primary interagency group that supports this effort is the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE), a formal group led by the Assistant Secretary for Preparedness and Response within the Department of Health and Human Services. We are proud that we have been supporting many of these agencies over the past eight years of our federal contract existence. As noted below, we provide contractual support to many of these agencies in their fulfillment of this mission.

♦ DHHS, ASPR: Planning, requirements generation, and epidemiologically based program analysis.

♦ BARDA: Project management, biomedical sciences support, clinical affairs and trial oversight, manufacturing engineering, regulatory and quality assurance services, and logistical planning.

♦ NIH, NIAID: Laboratory sciences for threat characterization and medical countermeasure discovery/testing.

♦ DHS, S&T: Project management for chemical and biological defense and subject matter expertise for biological threat characterization

♦ DoD: Research management in infectious diseases, regenerative medicine and trauma care

♦ PHEMCE Working Group/Committee participation: CBRN and Influenza groups

|Contact Us

For more about our company, products or services.

Contact Us»